ArticleJournal of translational medicine2026
Cerebrospinal fluid dopamine 3-O-sulfate as a novel biomarker for predicting motor complications in Parkinson's disease: insights from the PPMI cohort.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLong-term levodopa treatment for Parkinson’s disease (PD) is often complicated by motor fluctuations and dyskinesia. Predictive biomarkers for these debilitating side effects are currently lacking, hindering personalized treatment.
objectivesThis study aimed to characterize the cerebrospinal fluid (CSF) metabolome across the PD continuum, distinguish disease-related from medication-related changes, and identify predictive biomarkers for levodopa-induced motor complications.
methodsWe analyzed targeted CSF metabolomic data from the Parkinson’s Progression Markers Initiative (PPMI) cohort, which included healthy controls, prodromal, and PD participants. Statistical analyses revealed differentially abundant metabolites. The association of the metabolite dopamine 3-O-sulfate (DA3S) with motor complications was assessed using logistic regression and decision tree models.
resultsDA3S was the most significantly altered metabolite in PD patients, with its elevation exclusively driven by levodopa treatment. DA3S levels were strongly correlated with levodopa exposure (LEDD) and demonstrated a significant independent association with the development of motor complications. A multivariable model combining DA3S, disease duration, and LEDD was used to predict motor complications, with an AUC of 0.806. A decision tree further confirmed the value of DA3S for risk stratification in specific patient subgroups.
conclusionsCSF DA3S is a pharmacodynamic marker of central levodopa metabolism and a robust, independent predictor of the onset of motor complications in PD patients. When combined with clinical variables, it facilitates effective risk stratification, providing a novel tool for personalizing therapy to mitigate treatment-related adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.